J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Robotics Systems Engineer

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
$117k - $201.3k+ Long-term incentive program
Senior, Expert
Bachelor's, Master's
Boston, MA, USA
Hybrid
Biology & BiotechBiomedical Engineering & Medical Devices

About the job

Requirements
  • A bachelor's or master's degree in Systems Engineering, Software Engineering, Mechatronics, Electrical Engineering, or a related field is required.
  • At least 8 years of experience in multidisciplinary systems engineering is required.
  • Experience with Class II or Class III medical devices is preferred.
  • Knowledge of embedded systems, firmware and software testing, and electromechanical systems is required.
  • At least 5 years of experience in surgical robotic systems or complex multidisciplinary medical devices is required.
  • A strong understanding of systems engineering principles and product development lifecycles, such as V-model, waterfall, or Agile, is required.
  • Experience with requirements management tools such as DOORS, Jama, or Polarion is required.
  • Familiarity with test automation tools and scripting languages such as Python, LabVIEW, or MATLAB is required.
  • Strong technical writing and communication skills are required.
  • Certification in CQE, CQA, or Six Sigma is a plus.
  • Proficiency in sample size calculation and statistical methods for analyzing data is required.
  • Preferred skills include computer programming, cost-benefit analysis, critical thinking, data science, industry analysis, innovation, manufacturing technologies, organizing, problem solving, process improvements, prototyping, quality assurance, quality control, research and development, robotic automation, SAP Product Lifecycle Management, and technical credibility.
  • Preferred skills also include coaching, critical thinking, innovation, Model-Based Systems Engineering (MBSE), organizing, project management, report writing, requirements analysis, research and development, researching, SAP Product Lifecycle Management, scripting languages, software acquisitions, software development management, software engineering practices, software quality assurance, systems development lifecycle, technological savvy, and training people.
Responsibilities
  • Lead systems engineering for a complex surgical robotic platform, including defining system architecture, decomposing system functionality, and developing clear, testable system and subsystem requirements.
  • Own the end-to-end requirements lifecycle, ensuring traceability from clinical user needs, surgeon workflows, and business objectives through system, subsystem, hardware, and software requirements and verification and validation.
  • Drive cross-functional collaboration across hardware, software, controls, mechanical, clinical, and verification and validation teams to ensure system requirements are technically sound, testable, and aligned with clinical use cases and robotic performance needs.
  • Lead system architecture development and integration of electromechanical hardware, embedded and application software, control algorithms, sensing, actuation, and user interaction in a safety-critical environment.
  • Lead system-level risk management in accordance with ISO 14971, including hazard analysis, risk control definition, verification of risk controls, and residual risk assessment focused on robotic behaviors, software contributions, and clinical use scenarios.
  • Own software-related system requirements, including system behaviors, operational concepts, user stories, and detailed clinical and technical use cases aligned with software functionality, system performance, and user workflows.
  • Ensure design control activities are executed in compliance with internal procedures and external regulatory requirements throughout the product lifecycle from concept through commercialization.
  • Lead system-level design and architecture reviews, drive cross-functional alignment, resolve technical trade-offs, and ensure readiness for regulatory submission and product release.
  • Define, control, and maintain system interfaces and interface specifications to ensure compatibility and robust integration across hardware, software, and mechanical domains.
  • Drive design-for-reliability practices, including robust design methodologies and Design of Experiments, across system and subsystem development.
  • Partner with Human Factors and Clinical Engineering to ensure usability requirements are met and use-related risks are mitigated.
  • Lead standards and regulatory compliance activities, including requirements flow-down and alignment with FDA 21 CFR Part 820, ISO 13485, IEC 60601, IEC 62304, ISO 14971, and other applicable standards.
  • Collaborate with reliability and test engineering teams to achieve reliability, durability, and service-life requirements, including supporting accelerated life testing and system-level reliability analysis.
  • Support design transfer and product launch activities, including manufacturing readiness, service considerations, and post-market surveillance of complaints, field issues, and failure analysis.
  • Apply Model-Based Systems Engineering and UML methods to define, analyze, and manage system architecture, requirements, interfaces, and behavior.
  • Lead investigations of nonconformances, deviations, and test failures; perform root cause analysis and drive corrective and preventive actions to closure.
  • Work with regulatory affairs, quality, manufacturing, and clinical teams to support audits, inspections, and regulatory submissions.
  • Communicate system-level risks, constraints, and opportunities to senior management, translating technical and clinical insights into business impact and actionable recommendations.
  • Identify critical paths and address development risks, facilitating structured problem-solving across R&D teams.
  • Support project planning, including input to resource and schedule planning.
Desired Qualifications
  • Experience with Class II or Class III medical devices.
  • Certification in CQE, CQA, or Six Sigma.
  • Preferred skills include computer programming, cost-benefit analysis, critical thinking, data science, industry analysis, innovation, manufacturing technologies, organizing, problem solving, process improvements, prototyping, quality assurance, quality control, research and development, robotic automation, SAP Product Lifecycle Management, and technical credibility.
  • Preferred skills also include coaching, critical thinking, innovation, Model-Based Systems Engineering (MBSE), organizing, project management, report writing, requirements analysis, research and development, researching, SAP Product Lifecycle Management, scripting languages, software acquisitions, software development management, software engineering practices, software quality assurance, systems development lifecycle, technological savvy, and training people.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.